Euglena (2931) 주식 개요유글레나는 일본에서 미세조류의 연구, 개발, 생산 및 판매에 종사하는 회사입니다. 자세히 보기2931 펀더멘털 분석스노우플레이크 점수가치 평가4/6미래 성장3/6과거 실적0/6재무 건전성5/6배당0/6강점공정 가치 추정치보다 낮은 20.4% 에서 거래수익은 매년 52.28% 증가할 것으로 예상됩니다.지난 5년 동안 수입이 매년 21.5% 증가했습니다.위험 분석우리의 위험 점검에서 2931에 대한 위험이 감지되지 않았습니다.모든 위험 점검 보기2931 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueJP¥Current PriceJP¥360.0032.4% 저평가 내재 할인율Growth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-7b58b2016201920222025202620282031Revenue JP¥57.9bEarnings JP¥5.6bAdvancedSet Fair ValueView all narrativesEuglena Co., Ltd. 경쟁사ShinnihonseiyakuSymbol: TSE:4931Market cap: JP¥40.3bCotaSymbol: TSE:4923Market cap: JP¥30.0bMilbonSymbol: TSE:4919Market cap: JP¥82.9bArtnatureSymbol: TSE:7823Market cap: JP¥26.3b가격 이력 및 성과Euglena 주가의 최고가, 최저가 및 변동 요약과거 주가현재 주가JP¥360.0052주 최고가JP¥513.0052주 최저가JP¥348.00베타-0.0951개월 변동-11.76%3개월 변동-5.51%1년 변동-19.28%3년 변동-60.44%5년 변동-56.15%IPO 이후 변동130.18%최근 뉴스 및 업데이트Buy Or Sell Opportunity • May 18Now 22% undervalued after recent price dropOver the last 90 days, the stock has fallen 10% to JP¥358. The fair value is estimated to be JP¥461, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 4.1% over the last 3 years. Earnings per share has grown by 66%.Board Change • Apr 09Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 4 experienced directors. 2 highly experienced directors. 3 independent directors (4 non-independent directors). Independent Outside Director Mirai Murakami was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Reported Earnings • Mar 27Full year 2025 earnings released: JP¥5.90 loss per share (vs JP¥4.84 loss in FY 2024)Full year 2025 results: JP¥5.90 loss per share (further deteriorated from JP¥4.84 loss in FY 2024). Revenue: JP¥50.4b (up 5.8% from FY 2024). Net loss: JP¥805.0m (loss widened 24% from FY 2024). Revenue is forecast to grow 2.6% p.a. on average during the next 3 years, compared to a 3.6% growth forecast for the Personal Products industry in Japan. Over the last 3 years on average, earnings per share has increased by 55% per year but the company’s share price has fallen by 26% per year, which means it is significantly lagging earnings.Buy Or Sell Opportunity • Mar 12Now 20% undervalued after recent price dropOver the last 90 days, the stock has fallen 9.1% to JP¥368. The fair value is estimated to be JP¥462, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 3.8% over the last 3 years. Earnings per share has grown by 55%.Reported Earnings • Feb 16Full year 2025 earnings released: JP¥5.90 loss per share (vs JP¥4.84 loss in FY 2024)Full year 2025 results: JP¥5.90 loss per share (further deteriorated from JP¥4.84 loss in FY 2024). Revenue: JP¥50.4b (up 5.8% from FY 2024). Net loss: JP¥805.0m (loss widened 24% from FY 2024). Over the last 3 years on average, earnings per share has increased by 55% per year but the company’s share price has fallen by 26% per year, which means it is significantly lagging earnings.공시 • Feb 16Euglena Co., Ltd., Annual General Meeting, Mar 24, 2026Euglena Co., Ltd., Annual General Meeting, Mar 24, 2026.더 많은 업데이트 보기Recent updatesBuy Or Sell Opportunity • May 18Now 22% undervalued after recent price dropOver the last 90 days, the stock has fallen 10% to JP¥358. The fair value is estimated to be JP¥461, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 4.1% over the last 3 years. Earnings per share has grown by 66%.Board Change • Apr 09Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 4 experienced directors. 2 highly experienced directors. 3 independent directors (4 non-independent directors). Independent Outside Director Mirai Murakami was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Reported Earnings • Mar 27Full year 2025 earnings released: JP¥5.90 loss per share (vs JP¥4.84 loss in FY 2024)Full year 2025 results: JP¥5.90 loss per share (further deteriorated from JP¥4.84 loss in FY 2024). Revenue: JP¥50.4b (up 5.8% from FY 2024). Net loss: JP¥805.0m (loss widened 24% from FY 2024). Revenue is forecast to grow 2.6% p.a. on average during the next 3 years, compared to a 3.6% growth forecast for the Personal Products industry in Japan. Over the last 3 years on average, earnings per share has increased by 55% per year but the company’s share price has fallen by 26% per year, which means it is significantly lagging earnings.Buy Or Sell Opportunity • Mar 12Now 20% undervalued after recent price dropOver the last 90 days, the stock has fallen 9.1% to JP¥368. The fair value is estimated to be JP¥462, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 3.8% over the last 3 years. Earnings per share has grown by 55%.Reported Earnings • Feb 16Full year 2025 earnings released: JP¥5.90 loss per share (vs JP¥4.84 loss in FY 2024)Full year 2025 results: JP¥5.90 loss per share (further deteriorated from JP¥4.84 loss in FY 2024). Revenue: JP¥50.4b (up 5.8% from FY 2024). Net loss: JP¥805.0m (loss widened 24% from FY 2024). Over the last 3 years on average, earnings per share has increased by 55% per year but the company’s share price has fallen by 26% per year, which means it is significantly lagging earnings.공시 • Feb 16Euglena Co., Ltd., Annual General Meeting, Mar 24, 2026Euglena Co., Ltd., Annual General Meeting, Mar 24, 2026.공시 • Dec 03Euglena Co., Ltd. to Report Fiscal Year 2025 Results on Feb 13, 2026Euglena Co., Ltd. announced that they will report fiscal year 2025 results on Feb 13, 2026Reported Earnings • Nov 16Third quarter 2025 earnings released: EPS: JP¥1.31 (vs JP¥1.40 loss in 3Q 2024)Third quarter 2025 results: EPS: JP¥1.31 (up from JP¥1.40 loss in 3Q 2024). Revenue: JP¥12.5b (up 4.6% from 3Q 2024). Net income: JP¥179.0m (up JP¥370.5m from 3Q 2024). Profit margin: 1.4% (up from net loss in 3Q 2024). The move to profitability was driven by higher revenue. Revenue is forecast to stay flat during the next 3 years compared to a 3.6% growth forecast for the Personal Products industry in Japan. Over the last 3 years on average, earnings per share has increased by 56% per year but the company’s share price has fallen by 21% per year, which means it is significantly lagging earnings.공시 • Sep 03Euglena Co., Ltd. to Report Q3, 2025 Results on Nov 13, 2025Euglena Co., Ltd. announced that they will report Q3, 2025 results on Nov 13, 2025공시 • Aug 19Euglena Co., Ltd. Provides Consolidated Earnings Guidance for the Year Ending December 31, 2025Euglena Co., Ltd. provided consolidated earnings guidance for the year ending December 31, 2025. For the year, the company expects net sales of JPY 50,000 million and operating profit of JPY 2,400 million.Reported Earnings • Aug 09Second quarter 2025 earnings released: JP¥0.38 loss per share (vs JP¥3.37 loss in 2Q 2024)Second quarter 2025 results: JP¥0.38 loss per share (improved from JP¥3.37 loss in 2Q 2024). Revenue: JP¥12.6b (up 1.0% from 2Q 2024). Net loss: JP¥52.0m (loss narrowed 89% from 2Q 2024). Revenue is forecast to grow 1.2% p.a. on average during the next 3 years, compared to a 4.0% growth forecast for the Personal Products industry in Japan.분석 기사 • Jul 28Here's Why Euglena (TSE:2931) Can Manage Its Debt ResponsiblyHoward Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...공시 • Jun 03Euglena Co., Ltd. to Report Q2, 2025 Results on Aug 08, 2025Euglena Co., Ltd. announced that they will report Q2, 2025 results on Aug 08, 2025Reported Earnings • May 13First quarter 2025 earnings released: JP¥3.72 loss per share (vs JP¥1.48 profit in 1Q 2024)First quarter 2025 results: JP¥3.72 loss per share (down from JP¥1.48 profit in 1Q 2024). Revenue: JP¥11.9b (up 7.0% from 1Q 2024). Net loss: JP¥507.0m (down 365% from profit in 1Q 2024). Revenue is forecast to grow 1.1% p.a. on average during the next 3 years, compared to a 3.9% growth forecast for the Personal Products industry in Japan.분석 기사 • Apr 15Euglena (TSE:2931) Has A Pretty Healthy Balance SheetThe external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...New Risk • Mar 23New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Japanese stocks, typically moving 7.5% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. This is currently the only risk that has been identified for the company.분석 기사 • Mar 19Returns At Euglena (TSE:2931) Are On The Way UpIf you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...공시 • Mar 01Euglena Co., Ltd. to Report Q1, 2025 Results on May 12, 2025Euglena Co., Ltd. announced that they will report Q1, 2025 results on May 12, 2025분석 기사 • Feb 18The Market Lifts Euglena Co., Ltd. (TSE:2931) Shares 30% But It Can Do MoreEuglena Co., Ltd. ( TSE:2931 ) shares have had a really impressive month, gaining 30% after a shaky period beforehand...New Risk • Feb 17New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Japanese stocks, typically moving 6.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.Reported Earnings • Feb 16Full year 2024 earnings released: JP¥4.84 loss per share (vs JP¥22.75 loss in FY 2023)Full year 2024 results: JP¥4.84 loss per share (improved from JP¥22.75 loss in FY 2023). Revenue: JP¥47.6b (up 2.4% from FY 2023). Net loss: JP¥650.0m (loss narrowed 76% from FY 2023). Over the last 3 years on average, earnings per share has increased by 44% per year but the company’s share price has fallen by 18% per year, which means it is significantly lagging earnings.공시 • Feb 14Euglena Co., Ltd., Annual General Meeting, Mar 28, 2025Euglena Co., Ltd., Annual General Meeting, Mar 28, 2025.공시 • Dec 03Euglena Co., Ltd. to Report Fiscal Year 2024 Results on Feb 14, 2025Euglena Co., Ltd. announced that they will report fiscal year 2024 results on Feb 14, 2025Reported Earnings • Nov 13Third quarter 2024 earnings released: JP¥5.73 loss per share (vs JP¥2.98 loss in 3Q 2023)Third quarter 2024 results: JP¥5.73 loss per share (further deteriorated from JP¥2.98 loss in 3Q 2023). Revenue: JP¥11.6b (up 3.1% from 3Q 2023). Net loss: JP¥781.0m (loss widened 124% from 3Q 2023). Revenue is forecast to grow 2.1% p.a. on average during the next 3 years, compared to a 4.6% growth forecast for the Personal Products industry in Japan. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has fallen by 24% per year, which means it is significantly lagging earnings.분석 기사 • Nov 13Would Euglena (TSE:2931) Be Better Off With Less Debt?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...공시 • Aug 27Euglena Co., Ltd. to Report Q3, 2024 Results on Nov 11, 2024Euglena Co., Ltd. announced that they will report Q3, 2024 results on Nov 11, 2024공시 • Aug 14Euglena Co., Ltd. Revises Consolidated Earnings Guidance for the Year Ended December 31, 2024Euglena Co., Ltd. revised consolidated earnings guidance for the year ended December 31, 2024. for the year, the company expects Net sales of JPY 48,000 million.New Risk • Jun 26New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Japanese stocks, typically moving 5.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (5.4% average weekly change). Shareholders have been diluted in the past year (16% increase in shares outstanding).공시 • Jun 02Euglena Co., Ltd. to Report Q2, 2024 Results on Aug 08, 2024Euglena Co., Ltd. announced that they will report Q2, 2024 results on Aug 08, 2024공시 • May 17Euglena Co., Ltd. Provides Consolidated Earnings Guidance for the Year Ended December 31, 2024Euglena Co., Ltd. provided consolidated earnings guidance for the year ended December 31, 2024. for the year, the company expects Net sales of JPY 52,500 million.Reported Earnings • May 16First quarter 2024 earnings released: EPS: JP¥1.48 (vs JP¥1.45 loss in 1Q 2023)First quarter 2024 results: EPS: JP¥1.48 (up from JP¥1.45 loss in 1Q 2023). Revenue: JP¥11.2b (up 2.9% from 1Q 2023). Net income: JP¥191.0m (up JP¥358.0m from 1Q 2023). Profit margin: 1.7% (up from net loss in 1Q 2023). Over the last 3 years on average, earnings per share has fallen by 4% per year but the company’s share price has fallen by 15% per year, which means it is performing significantly worse than earnings.공시 • Mar 29Euglena Co., Ltd. to Report Q1, 2024 Results on May 13, 2024Euglena Co., Ltd. announced that they will report Q1, 2024 results on May 13, 2024Reported Earnings • Mar 27Full year 2023 earnings released: JP¥22.75 loss per share (vs JP¥23.83 loss in FY 2022)Full year 2023 results: JP¥22.75 loss per share (improved from JP¥23.83 loss in FY 2022). Revenue: JP¥46.5b (up 4.7% from FY 2022). Net loss: JP¥2.65b (flat on FY 2022). Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has fallen by 17% per year, which means it is performing significantly worse than earnings.공시 • Feb 16Euglena Co., Ltd., Annual General Meeting, Mar 19, 2024Euglena Co., Ltd., Annual General Meeting, Mar 19, 2024.Reported Earnings • Feb 16Full year 2023 earnings released: JP¥22.75 loss per share (vs JP¥23.83 loss in FY 2022)Full year 2023 results: JP¥22.75 loss per share (improved from JP¥23.83 loss in FY 2022). Revenue: JP¥46.5b (up 4.7% from FY 2022). Net loss: JP¥2.65b (flat on FY 2022). Over the last 3 years on average, earnings per share has fallen by 11% per year whereas the company’s share price has fallen by 14% per year.공시 • Jan 25Zenhoren Co.,Ltd. (TSE:5845) agreed to acquire 18.93% stake in Okinawa Basketball Co., Ltd from Euglena Co., Ltd. (TSE:2931) for ¥360 million.Zenhoren Co.,Ltd. (TSE:5845) agreed to acquire 18.93% stake in Okinawa Basketball Co., Ltd from Euglena Co., Ltd. (TSE:2931) for ¥360 million on January 24, 2024. As part of acquisition, 480 shares will be acquired for ¥0.75 million. The transaction is expected to complete on January 31, 2024.공시 • Jan 12Euglena Co., Ltd. (TSE:2931) agreed to acquire Saticine Medical Co., Ltd.Euglena Co., Ltd. (TSE:2931) agreed to acquire Saticine Medical Co., Ltd. on January 10, 2024.Board Change • Jan 02Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 3 highly experienced directors. Independent Outside Director Aiko Mochizuki was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.공시 • Dec 05Euglena Co., Ltd. to Report Fiscal Year 2023 Results on Feb 14, 2024Euglena Co., Ltd. announced that they will report fiscal year 2023 results on Feb 14, 2024Reported Earnings • Nov 15Third quarter 2023 earnings released: JP¥2.98 loss per share (vs JP¥15.91 loss in 3Q 2022)Third quarter 2023 results: JP¥2.98 loss per share (improved from JP¥15.91 loss in 3Q 2022). Revenue: JP¥11.3b (down 6.5% from 3Q 2022). Net loss: JP¥349.0m (loss narrowed 81% from 3Q 2022). Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has only fallen by 2% per year, which means it has not declined as severely as earnings.공시 • Sep 02Euglena Co., Ltd. to Report Q3, 2023 Results on Nov 13, 2023Euglena Co., Ltd. announced that they will report Q3, 2023 results on Nov 13, 2023Reported Earnings • Aug 16Second quarter 2023 earnings releasedSecond quarter 2023 results: JP¥6.38 loss per share. Net loss: JP¥747.0m (flat on 2Q 2022). Revenue is forecast to stay flat during the next 3 years compared to a 4.2% growth forecast for the Personal Products industry in Japan. Over the last 3 years on average, earnings per share has fallen by 3% per year whereas the company’s share price has remained flat.공시 • Jun 28Euglena Co., Ltd. to Report Q2, 2023 Results on Aug 14, 2023Euglena Co., Ltd. announced that they will report Q2, 2023 results on Aug 14, 2023Reported Earnings • May 17First quarter 2023 earnings releasedFirst quarter 2023 results: JP¥1.45 loss per share. Net loss: JP¥167.0m (flat on 1Q 2022). Revenue is forecast to grow 1.0% p.a. on average during the next 3 years, compared to a 4.6% growth forecast for the Personal Products industry in Japan. Over the last 3 years on average, earnings per share has increased by 6% per year whereas the company’s share price has increased by 8% per year.Reported Earnings • Mar 31Full year 2022 earnings released: JP¥23.83 loss per share (vs JP¥44.51 loss in FY 2021)Full year 2022 results: JP¥23.83 loss per share (improved from JP¥44.51 loss in FY 2021). Revenue: JP¥44.4b (up 46% from FY 2021). Net loss: JP¥2.67b (loss narrowed 43% from FY 2021). Revenue is forecast to stay flat during the next 3 years compared to a 4.1% growth forecast for the Personal Products industry in Japan. Over the last 3 years on average, earnings per share has increased by 14% per year whereas the company’s share price has increased by 12% per year.Price Target Changed • Mar 24Price target increased by 11% to JP¥1,000Up from JP¥900, the current price target is provided by 1 analyst. New target price is 10% above last closing price of JP¥906. Stock is up 10% over the past year. The company is forecast to post a net loss per share of JP¥11.50 next year compared to a net loss per share of JP¥23.83 last year.공시 • Feb 16Euglena Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending Dec. 31, 2023Euglena Co., Ltd. provided consolidated earnings guidance for the fiscal year ending Dec. 31, 2023. The company expects net sales to be JPY 45,000 million.공시 • Feb 15Euglena Co., Ltd., Annual General Meeting, Mar 24, 2023Euglena Co., Ltd., Annual General Meeting, Mar 24, 2023.Reported Earnings • Feb 14Full year 2022 earnings released: JP¥23.83 loss per share (vs JP¥44.51 loss in FY 2021)Full year 2022 results: JP¥23.83 loss per share (improved from JP¥44.51 loss in FY 2021). Revenue: JP¥44.4b (up 46% from FY 2021). Net loss: JP¥2.67b (loss narrowed 43% from FY 2021). Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth.공시 • Feb 08Euglena Co., Ltd. announced that it has received ¥7.7999475 billion in funding from Marui Group Co., Ltd., Rohto Pharmaceutical Co.,Ltd., Mazda Motor Corporation, Dai-ichi Life Holdings, Inc.On February 6, 2023, Euglena Co., Ltd. closed the transaction.공시 • Jan 20Euglena Co., Ltd. announced that it expects to receive ¥7.7999475 billion in funding from Marui Group Co., Ltd., Rohto Pharmaceutical Co.,Ltd.Euglena Co., Ltd. announced that it will issue 3,208,500 common shares at a price of ¥935 for gross proceeds of ¥2,999,947,500 and 48 convertible bond-type bonds with stock acquisition rights at a price of ¥100,000,000 for gross proceeds of ¥4,800,000,000 for aggregate gross proceeds of ¥4,785,000,000 on January 19, 2023. The transaction will include participation from Marui Group Co., Ltd. of 2,139,000 shares and Rohto Pharmaceutical Co.,Ltd. of 1,069,500 shares post completion of the transaction. The company is issuing securities through third party allotment. The 10th stock acquisition rights are convertible into 5,133,689 shares. The transaction is expected to close on February 6, 2023. The transaction has been approved by the board of directors of the company.공시 • Dec 28Euglena Co., Ltd. to Report Fiscal Year 2022 Results on Feb 13, 2023Euglena Co., Ltd. announced that they will report fiscal year 2022 results on Feb 13, 2023Reported Earnings • Apr 02Full year 2021 earnings released: JP¥39.26 loss per share (vs JP¥17.15 loss in FY 2020)Full year 2021 results: JP¥39.26 loss per share (down from JP¥17.15 loss in FY 2020). Revenue: JP¥27.5b (up 97% from FY 2020). Net loss: JP¥4.03b (loss widened 153% from FY 2020). Over the last 3 years on average, earnings per share has increased by 55% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth.Reported Earnings • Feb 12Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: JP¥44.51 loss per share (down from JP¥17.15 loss in FY 2020). Revenue: JP¥30.5b (up 118% from FY 2020). Net loss: JP¥4.68b (loss widened 194% from FY 2020). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 53% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth.Reported Earnings • May 17Second quarter 2021 earnings released: EPS JP¥1.75 (vs JP¥1.17 in 2Q 2020)The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: JP¥3.83b (up 34% from 2Q 2020). Net income: JP¥164.0m (up 51% from 2Q 2020). Profit margin: 4.3% (up from 3.8% in 2Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings.Is New 90 Day High Low • Mar 16New 90-day high: JP¥1,264The company is up 58% from a price of JP¥799 on 16 December 2020. Outperformed the Japanese market which is up 10.0% over the last 90 days. Exceeded the Personal Products industry, which is flat over the same period.Reported Earnings • Feb 17First quarter 2021 earnings released: JP¥3.87 loss per share (vs JP¥2.71 loss in 1Q 2020)The company reported a soft first quarter result with increased losses and weaker control over costs, although revenues improved. First quarter 2021 results: Revenue: JP¥3.91b (up 22% from 1Q 2020). Net loss: JP¥360.0m (loss widened 43% from 1Q 2020). Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has only fallen by 1% per year, which means it has not declined as severely as earnings.Is New 90 Day High Low • Feb 05New 90-day high: JP¥909The company is up 4.0% from its price of JP¥871 on 06 November 2020. The Japanese market is up 12% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Personal Products industry, which is up 2.0% over the same period.Reported Earnings • Dec 27Full year 2020 earnings released: JP¥16.00 loss per shareThe company reported a decent full year result with reduced losses and improved control over expenses, although revenues were weaker. Full year 2020 results: Revenue: JP¥13.3b (down 4.7% from FY 2019). Net loss: JP¥1.49b (loss narrowed 85% from FY 2019). Over the last 3 years on average, earnings per share has fallen by 42% per year but the company’s share price has only fallen by 9% per year, which means it has not declined as severely as earnings.Is New 90 Day High Low • Dec 23New 90-day low: JP¥774The company is down 16% from its price of JP¥917 on 24 September 2020. The Japanese market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 5.0% over the same period.Is New 90 Day High Low • Dec 07New 90-day low: JP¥797The company is down 4.0% from its price of JP¥830 on 08 September 2020. The Japanese market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 12% over the same period.주주 수익률2931JP Personal ProductsJP 시장7D-1.6%-1.5%3.4%1Y-19.3%2.5%43.2%전체 주주 수익률 보기수익률 대 산업: 2931은 지난 1년 동안 2.5%의 수익을 기록한 JP Personal Products 산업보다 저조한 성과를 냈습니다.수익률 대 시장: 2931은 지난 1년 동안 43.2%를 기록한 JP 시장보다 저조한 성과를 냈습니다.주가 변동성Is 2931's price volatile compared to industry and market?2931 volatility2931 Average Weekly Movement4.8%Personal Products Industry Average Movement4.1%Market Average Movement5.0%10% most volatile stocks in JP Market9.7%10% least volatile stocks in JP Market2.5%안정적인 주가: 2931는 지난 3개월 동안 JP 시장에 비해 주가 변동성이 크지 않았습니다.시간에 따른 변동성: 2931의 주간 변동성(5%)은 지난 1년 동안 안정적이었습니다.회사 소개설립직원 수CEO웹사이트2005793Tomohiro Wakaharawww.euglena.jp유글레나 주식회사는 일본에서 미세조류의 연구, 개발, 생산 및 판매에 종사하고 있습니다. 또한 유글레나를 이용한 식품과 화장품을 제조 및 판매하고 있습니다. 또한 미세조류의 바이오 연료 기술 및 환경 관련 기술을 개발하고 생명공학 관련 사업에도 투자하고 있습니다.더 보기Euglena Co., Ltd. 기초 지표 요약Euglena의 순이익과 매출은 시가총액과 어떻게 비교됩니까?2931 기초 통계시가총액JP¥49.57b순이익 (TTM)-JP¥330.00m매출 (TTM)JP¥51.63b1.0x주가매출비율(P/S)-151.9x주가수익비율(P/E)2931는 고평가되어 있습니까?공정 가치 및 평가 분석 보기순이익 및 매출최근 실적 보고서(TTM)의 주요 수익성 지표2931 손익계산서 (TTM)매출JP¥51.63b매출원가JP¥15.94b총이익JP¥35.69b기타 비용JP¥36.02b순이익-JP¥330.00m최근 보고된 실적Mar 31, 2026다음 실적 발표일해당 없음주당순이익(EPS)-2.37총이익률69.13%순이익률-0.64%부채/자본 비율82.5%2931의 장기 실적은 어땠습니까?과거 실적 및 비교 보기배당0.6%현재 배당 수익률-83%배당 성향View Valuation기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/26 09:42종가2026/05/26 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Euglena Co., Ltd.는 1명의 분석가가 다루고 있습니다. 이 중 1명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Shima YamanakaSMBC NIKKO
Buy Or Sell Opportunity • May 18Now 22% undervalued after recent price dropOver the last 90 days, the stock has fallen 10% to JP¥358. The fair value is estimated to be JP¥461, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 4.1% over the last 3 years. Earnings per share has grown by 66%.
Board Change • Apr 09Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 4 experienced directors. 2 highly experienced directors. 3 independent directors (4 non-independent directors). Independent Outside Director Mirai Murakami was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Reported Earnings • Mar 27Full year 2025 earnings released: JP¥5.90 loss per share (vs JP¥4.84 loss in FY 2024)Full year 2025 results: JP¥5.90 loss per share (further deteriorated from JP¥4.84 loss in FY 2024). Revenue: JP¥50.4b (up 5.8% from FY 2024). Net loss: JP¥805.0m (loss widened 24% from FY 2024). Revenue is forecast to grow 2.6% p.a. on average during the next 3 years, compared to a 3.6% growth forecast for the Personal Products industry in Japan. Over the last 3 years on average, earnings per share has increased by 55% per year but the company’s share price has fallen by 26% per year, which means it is significantly lagging earnings.
Buy Or Sell Opportunity • Mar 12Now 20% undervalued after recent price dropOver the last 90 days, the stock has fallen 9.1% to JP¥368. The fair value is estimated to be JP¥462, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 3.8% over the last 3 years. Earnings per share has grown by 55%.
Reported Earnings • Feb 16Full year 2025 earnings released: JP¥5.90 loss per share (vs JP¥4.84 loss in FY 2024)Full year 2025 results: JP¥5.90 loss per share (further deteriorated from JP¥4.84 loss in FY 2024). Revenue: JP¥50.4b (up 5.8% from FY 2024). Net loss: JP¥805.0m (loss widened 24% from FY 2024). Over the last 3 years on average, earnings per share has increased by 55% per year but the company’s share price has fallen by 26% per year, which means it is significantly lagging earnings.
공시 • Feb 16Euglena Co., Ltd., Annual General Meeting, Mar 24, 2026Euglena Co., Ltd., Annual General Meeting, Mar 24, 2026.
Buy Or Sell Opportunity • May 18Now 22% undervalued after recent price dropOver the last 90 days, the stock has fallen 10% to JP¥358. The fair value is estimated to be JP¥461, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 4.1% over the last 3 years. Earnings per share has grown by 66%.
Board Change • Apr 09Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 4 experienced directors. 2 highly experienced directors. 3 independent directors (4 non-independent directors). Independent Outside Director Mirai Murakami was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Reported Earnings • Mar 27Full year 2025 earnings released: JP¥5.90 loss per share (vs JP¥4.84 loss in FY 2024)Full year 2025 results: JP¥5.90 loss per share (further deteriorated from JP¥4.84 loss in FY 2024). Revenue: JP¥50.4b (up 5.8% from FY 2024). Net loss: JP¥805.0m (loss widened 24% from FY 2024). Revenue is forecast to grow 2.6% p.a. on average during the next 3 years, compared to a 3.6% growth forecast for the Personal Products industry in Japan. Over the last 3 years on average, earnings per share has increased by 55% per year but the company’s share price has fallen by 26% per year, which means it is significantly lagging earnings.
Buy Or Sell Opportunity • Mar 12Now 20% undervalued after recent price dropOver the last 90 days, the stock has fallen 9.1% to JP¥368. The fair value is estimated to be JP¥462, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 3.8% over the last 3 years. Earnings per share has grown by 55%.
Reported Earnings • Feb 16Full year 2025 earnings released: JP¥5.90 loss per share (vs JP¥4.84 loss in FY 2024)Full year 2025 results: JP¥5.90 loss per share (further deteriorated from JP¥4.84 loss in FY 2024). Revenue: JP¥50.4b (up 5.8% from FY 2024). Net loss: JP¥805.0m (loss widened 24% from FY 2024). Over the last 3 years on average, earnings per share has increased by 55% per year but the company’s share price has fallen by 26% per year, which means it is significantly lagging earnings.
공시 • Feb 16Euglena Co., Ltd., Annual General Meeting, Mar 24, 2026Euglena Co., Ltd., Annual General Meeting, Mar 24, 2026.
공시 • Dec 03Euglena Co., Ltd. to Report Fiscal Year 2025 Results on Feb 13, 2026Euglena Co., Ltd. announced that they will report fiscal year 2025 results on Feb 13, 2026
Reported Earnings • Nov 16Third quarter 2025 earnings released: EPS: JP¥1.31 (vs JP¥1.40 loss in 3Q 2024)Third quarter 2025 results: EPS: JP¥1.31 (up from JP¥1.40 loss in 3Q 2024). Revenue: JP¥12.5b (up 4.6% from 3Q 2024). Net income: JP¥179.0m (up JP¥370.5m from 3Q 2024). Profit margin: 1.4% (up from net loss in 3Q 2024). The move to profitability was driven by higher revenue. Revenue is forecast to stay flat during the next 3 years compared to a 3.6% growth forecast for the Personal Products industry in Japan. Over the last 3 years on average, earnings per share has increased by 56% per year but the company’s share price has fallen by 21% per year, which means it is significantly lagging earnings.
공시 • Sep 03Euglena Co., Ltd. to Report Q3, 2025 Results on Nov 13, 2025Euglena Co., Ltd. announced that they will report Q3, 2025 results on Nov 13, 2025
공시 • Aug 19Euglena Co., Ltd. Provides Consolidated Earnings Guidance for the Year Ending December 31, 2025Euglena Co., Ltd. provided consolidated earnings guidance for the year ending December 31, 2025. For the year, the company expects net sales of JPY 50,000 million and operating profit of JPY 2,400 million.
Reported Earnings • Aug 09Second quarter 2025 earnings released: JP¥0.38 loss per share (vs JP¥3.37 loss in 2Q 2024)Second quarter 2025 results: JP¥0.38 loss per share (improved from JP¥3.37 loss in 2Q 2024). Revenue: JP¥12.6b (up 1.0% from 2Q 2024). Net loss: JP¥52.0m (loss narrowed 89% from 2Q 2024). Revenue is forecast to grow 1.2% p.a. on average during the next 3 years, compared to a 4.0% growth forecast for the Personal Products industry in Japan.
분석 기사 • Jul 28Here's Why Euglena (TSE:2931) Can Manage Its Debt ResponsiblyHoward Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
공시 • Jun 03Euglena Co., Ltd. to Report Q2, 2025 Results on Aug 08, 2025Euglena Co., Ltd. announced that they will report Q2, 2025 results on Aug 08, 2025
Reported Earnings • May 13First quarter 2025 earnings released: JP¥3.72 loss per share (vs JP¥1.48 profit in 1Q 2024)First quarter 2025 results: JP¥3.72 loss per share (down from JP¥1.48 profit in 1Q 2024). Revenue: JP¥11.9b (up 7.0% from 1Q 2024). Net loss: JP¥507.0m (down 365% from profit in 1Q 2024). Revenue is forecast to grow 1.1% p.a. on average during the next 3 years, compared to a 3.9% growth forecast for the Personal Products industry in Japan.
분석 기사 • Apr 15Euglena (TSE:2931) Has A Pretty Healthy Balance SheetThe external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
New Risk • Mar 23New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Japanese stocks, typically moving 7.5% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. This is currently the only risk that has been identified for the company.
분석 기사 • Mar 19Returns At Euglena (TSE:2931) Are On The Way UpIf you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...
공시 • Mar 01Euglena Co., Ltd. to Report Q1, 2025 Results on May 12, 2025Euglena Co., Ltd. announced that they will report Q1, 2025 results on May 12, 2025
분석 기사 • Feb 18The Market Lifts Euglena Co., Ltd. (TSE:2931) Shares 30% But It Can Do MoreEuglena Co., Ltd. ( TSE:2931 ) shares have had a really impressive month, gaining 30% after a shaky period beforehand...
New Risk • Feb 17New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Japanese stocks, typically moving 6.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.
Reported Earnings • Feb 16Full year 2024 earnings released: JP¥4.84 loss per share (vs JP¥22.75 loss in FY 2023)Full year 2024 results: JP¥4.84 loss per share (improved from JP¥22.75 loss in FY 2023). Revenue: JP¥47.6b (up 2.4% from FY 2023). Net loss: JP¥650.0m (loss narrowed 76% from FY 2023). Over the last 3 years on average, earnings per share has increased by 44% per year but the company’s share price has fallen by 18% per year, which means it is significantly lagging earnings.
공시 • Feb 14Euglena Co., Ltd., Annual General Meeting, Mar 28, 2025Euglena Co., Ltd., Annual General Meeting, Mar 28, 2025.
공시 • Dec 03Euglena Co., Ltd. to Report Fiscal Year 2024 Results on Feb 14, 2025Euglena Co., Ltd. announced that they will report fiscal year 2024 results on Feb 14, 2025
Reported Earnings • Nov 13Third quarter 2024 earnings released: JP¥5.73 loss per share (vs JP¥2.98 loss in 3Q 2023)Third quarter 2024 results: JP¥5.73 loss per share (further deteriorated from JP¥2.98 loss in 3Q 2023). Revenue: JP¥11.6b (up 3.1% from 3Q 2023). Net loss: JP¥781.0m (loss widened 124% from 3Q 2023). Revenue is forecast to grow 2.1% p.a. on average during the next 3 years, compared to a 4.6% growth forecast for the Personal Products industry in Japan. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has fallen by 24% per year, which means it is significantly lagging earnings.
분석 기사 • Nov 13Would Euglena (TSE:2931) Be Better Off With Less Debt?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
공시 • Aug 27Euglena Co., Ltd. to Report Q3, 2024 Results on Nov 11, 2024Euglena Co., Ltd. announced that they will report Q3, 2024 results on Nov 11, 2024
공시 • Aug 14Euglena Co., Ltd. Revises Consolidated Earnings Guidance for the Year Ended December 31, 2024Euglena Co., Ltd. revised consolidated earnings guidance for the year ended December 31, 2024. for the year, the company expects Net sales of JPY 48,000 million.
New Risk • Jun 26New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Japanese stocks, typically moving 5.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (5.4% average weekly change). Shareholders have been diluted in the past year (16% increase in shares outstanding).
공시 • Jun 02Euglena Co., Ltd. to Report Q2, 2024 Results on Aug 08, 2024Euglena Co., Ltd. announced that they will report Q2, 2024 results on Aug 08, 2024
공시 • May 17Euglena Co., Ltd. Provides Consolidated Earnings Guidance for the Year Ended December 31, 2024Euglena Co., Ltd. provided consolidated earnings guidance for the year ended December 31, 2024. for the year, the company expects Net sales of JPY 52,500 million.
Reported Earnings • May 16First quarter 2024 earnings released: EPS: JP¥1.48 (vs JP¥1.45 loss in 1Q 2023)First quarter 2024 results: EPS: JP¥1.48 (up from JP¥1.45 loss in 1Q 2023). Revenue: JP¥11.2b (up 2.9% from 1Q 2023). Net income: JP¥191.0m (up JP¥358.0m from 1Q 2023). Profit margin: 1.7% (up from net loss in 1Q 2023). Over the last 3 years on average, earnings per share has fallen by 4% per year but the company’s share price has fallen by 15% per year, which means it is performing significantly worse than earnings.
공시 • Mar 29Euglena Co., Ltd. to Report Q1, 2024 Results on May 13, 2024Euglena Co., Ltd. announced that they will report Q1, 2024 results on May 13, 2024
Reported Earnings • Mar 27Full year 2023 earnings released: JP¥22.75 loss per share (vs JP¥23.83 loss in FY 2022)Full year 2023 results: JP¥22.75 loss per share (improved from JP¥23.83 loss in FY 2022). Revenue: JP¥46.5b (up 4.7% from FY 2022). Net loss: JP¥2.65b (flat on FY 2022). Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has fallen by 17% per year, which means it is performing significantly worse than earnings.
공시 • Feb 16Euglena Co., Ltd., Annual General Meeting, Mar 19, 2024Euglena Co., Ltd., Annual General Meeting, Mar 19, 2024.
Reported Earnings • Feb 16Full year 2023 earnings released: JP¥22.75 loss per share (vs JP¥23.83 loss in FY 2022)Full year 2023 results: JP¥22.75 loss per share (improved from JP¥23.83 loss in FY 2022). Revenue: JP¥46.5b (up 4.7% from FY 2022). Net loss: JP¥2.65b (flat on FY 2022). Over the last 3 years on average, earnings per share has fallen by 11% per year whereas the company’s share price has fallen by 14% per year.
공시 • Jan 25Zenhoren Co.,Ltd. (TSE:5845) agreed to acquire 18.93% stake in Okinawa Basketball Co., Ltd from Euglena Co., Ltd. (TSE:2931) for ¥360 million.Zenhoren Co.,Ltd. (TSE:5845) agreed to acquire 18.93% stake in Okinawa Basketball Co., Ltd from Euglena Co., Ltd. (TSE:2931) for ¥360 million on January 24, 2024. As part of acquisition, 480 shares will be acquired for ¥0.75 million. The transaction is expected to complete on January 31, 2024.
공시 • Jan 12Euglena Co., Ltd. (TSE:2931) agreed to acquire Saticine Medical Co., Ltd.Euglena Co., Ltd. (TSE:2931) agreed to acquire Saticine Medical Co., Ltd. on January 10, 2024.
Board Change • Jan 02Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 3 highly experienced directors. Independent Outside Director Aiko Mochizuki was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
공시 • Dec 05Euglena Co., Ltd. to Report Fiscal Year 2023 Results on Feb 14, 2024Euglena Co., Ltd. announced that they will report fiscal year 2023 results on Feb 14, 2024
Reported Earnings • Nov 15Third quarter 2023 earnings released: JP¥2.98 loss per share (vs JP¥15.91 loss in 3Q 2022)Third quarter 2023 results: JP¥2.98 loss per share (improved from JP¥15.91 loss in 3Q 2022). Revenue: JP¥11.3b (down 6.5% from 3Q 2022). Net loss: JP¥349.0m (loss narrowed 81% from 3Q 2022). Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has only fallen by 2% per year, which means it has not declined as severely as earnings.
공시 • Sep 02Euglena Co., Ltd. to Report Q3, 2023 Results on Nov 13, 2023Euglena Co., Ltd. announced that they will report Q3, 2023 results on Nov 13, 2023
Reported Earnings • Aug 16Second quarter 2023 earnings releasedSecond quarter 2023 results: JP¥6.38 loss per share. Net loss: JP¥747.0m (flat on 2Q 2022). Revenue is forecast to stay flat during the next 3 years compared to a 4.2% growth forecast for the Personal Products industry in Japan. Over the last 3 years on average, earnings per share has fallen by 3% per year whereas the company’s share price has remained flat.
공시 • Jun 28Euglena Co., Ltd. to Report Q2, 2023 Results on Aug 14, 2023Euglena Co., Ltd. announced that they will report Q2, 2023 results on Aug 14, 2023
Reported Earnings • May 17First quarter 2023 earnings releasedFirst quarter 2023 results: JP¥1.45 loss per share. Net loss: JP¥167.0m (flat on 1Q 2022). Revenue is forecast to grow 1.0% p.a. on average during the next 3 years, compared to a 4.6% growth forecast for the Personal Products industry in Japan. Over the last 3 years on average, earnings per share has increased by 6% per year whereas the company’s share price has increased by 8% per year.
Reported Earnings • Mar 31Full year 2022 earnings released: JP¥23.83 loss per share (vs JP¥44.51 loss in FY 2021)Full year 2022 results: JP¥23.83 loss per share (improved from JP¥44.51 loss in FY 2021). Revenue: JP¥44.4b (up 46% from FY 2021). Net loss: JP¥2.67b (loss narrowed 43% from FY 2021). Revenue is forecast to stay flat during the next 3 years compared to a 4.1% growth forecast for the Personal Products industry in Japan. Over the last 3 years on average, earnings per share has increased by 14% per year whereas the company’s share price has increased by 12% per year.
Price Target Changed • Mar 24Price target increased by 11% to JP¥1,000Up from JP¥900, the current price target is provided by 1 analyst. New target price is 10% above last closing price of JP¥906. Stock is up 10% over the past year. The company is forecast to post a net loss per share of JP¥11.50 next year compared to a net loss per share of JP¥23.83 last year.
공시 • Feb 16Euglena Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending Dec. 31, 2023Euglena Co., Ltd. provided consolidated earnings guidance for the fiscal year ending Dec. 31, 2023. The company expects net sales to be JPY 45,000 million.
공시 • Feb 15Euglena Co., Ltd., Annual General Meeting, Mar 24, 2023Euglena Co., Ltd., Annual General Meeting, Mar 24, 2023.
Reported Earnings • Feb 14Full year 2022 earnings released: JP¥23.83 loss per share (vs JP¥44.51 loss in FY 2021)Full year 2022 results: JP¥23.83 loss per share (improved from JP¥44.51 loss in FY 2021). Revenue: JP¥44.4b (up 46% from FY 2021). Net loss: JP¥2.67b (loss narrowed 43% from FY 2021). Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth.
공시 • Feb 08Euglena Co., Ltd. announced that it has received ¥7.7999475 billion in funding from Marui Group Co., Ltd., Rohto Pharmaceutical Co.,Ltd., Mazda Motor Corporation, Dai-ichi Life Holdings, Inc.On February 6, 2023, Euglena Co., Ltd. closed the transaction.
공시 • Jan 20Euglena Co., Ltd. announced that it expects to receive ¥7.7999475 billion in funding from Marui Group Co., Ltd., Rohto Pharmaceutical Co.,Ltd.Euglena Co., Ltd. announced that it will issue 3,208,500 common shares at a price of ¥935 for gross proceeds of ¥2,999,947,500 and 48 convertible bond-type bonds with stock acquisition rights at a price of ¥100,000,000 for gross proceeds of ¥4,800,000,000 for aggregate gross proceeds of ¥4,785,000,000 on January 19, 2023. The transaction will include participation from Marui Group Co., Ltd. of 2,139,000 shares and Rohto Pharmaceutical Co.,Ltd. of 1,069,500 shares post completion of the transaction. The company is issuing securities through third party allotment. The 10th stock acquisition rights are convertible into 5,133,689 shares. The transaction is expected to close on February 6, 2023. The transaction has been approved by the board of directors of the company.
공시 • Dec 28Euglena Co., Ltd. to Report Fiscal Year 2022 Results on Feb 13, 2023Euglena Co., Ltd. announced that they will report fiscal year 2022 results on Feb 13, 2023
Reported Earnings • Apr 02Full year 2021 earnings released: JP¥39.26 loss per share (vs JP¥17.15 loss in FY 2020)Full year 2021 results: JP¥39.26 loss per share (down from JP¥17.15 loss in FY 2020). Revenue: JP¥27.5b (up 97% from FY 2020). Net loss: JP¥4.03b (loss widened 153% from FY 2020). Over the last 3 years on average, earnings per share has increased by 55% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Feb 12Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: JP¥44.51 loss per share (down from JP¥17.15 loss in FY 2020). Revenue: JP¥30.5b (up 118% from FY 2020). Net loss: JP¥4.68b (loss widened 194% from FY 2020). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 53% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth.
Reported Earnings • May 17Second quarter 2021 earnings released: EPS JP¥1.75 (vs JP¥1.17 in 2Q 2020)The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: JP¥3.83b (up 34% from 2Q 2020). Net income: JP¥164.0m (up 51% from 2Q 2020). Profit margin: 4.3% (up from 3.8% in 2Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings.
Is New 90 Day High Low • Mar 16New 90-day high: JP¥1,264The company is up 58% from a price of JP¥799 on 16 December 2020. Outperformed the Japanese market which is up 10.0% over the last 90 days. Exceeded the Personal Products industry, which is flat over the same period.
Reported Earnings • Feb 17First quarter 2021 earnings released: JP¥3.87 loss per share (vs JP¥2.71 loss in 1Q 2020)The company reported a soft first quarter result with increased losses and weaker control over costs, although revenues improved. First quarter 2021 results: Revenue: JP¥3.91b (up 22% from 1Q 2020). Net loss: JP¥360.0m (loss widened 43% from 1Q 2020). Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has only fallen by 1% per year, which means it has not declined as severely as earnings.
Is New 90 Day High Low • Feb 05New 90-day high: JP¥909The company is up 4.0% from its price of JP¥871 on 06 November 2020. The Japanese market is up 12% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Personal Products industry, which is up 2.0% over the same period.
Reported Earnings • Dec 27Full year 2020 earnings released: JP¥16.00 loss per shareThe company reported a decent full year result with reduced losses and improved control over expenses, although revenues were weaker. Full year 2020 results: Revenue: JP¥13.3b (down 4.7% from FY 2019). Net loss: JP¥1.49b (loss narrowed 85% from FY 2019). Over the last 3 years on average, earnings per share has fallen by 42% per year but the company’s share price has only fallen by 9% per year, which means it has not declined as severely as earnings.
Is New 90 Day High Low • Dec 23New 90-day low: JP¥774The company is down 16% from its price of JP¥917 on 24 September 2020. The Japanese market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 5.0% over the same period.
Is New 90 Day High Low • Dec 07New 90-day low: JP¥797The company is down 4.0% from its price of JP¥830 on 08 September 2020. The Japanese market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 12% over the same period.
